BriaCell

BriaCell is a biotechnology company specializing in immuno-oncology, dedicated to developing targeted and safe cancer treatments, including the first off-the-shelf personalized approach to immunotherapy. The company recently achieved positive proof-of-concept in a Phase I/IIa clinical trial of its lead candidate drug, Bria-IMT™, for advanced breast cancer patients (ClinicalTrials.gov, NCT03066947). This trial is being conducted alongside the co-development of the company's companion diagnostic test, BriaDX™. Utilizing Bria-IMT™, BriaCell is advancing the development of Bria-OTS™, the first "off-the-shelf" personalized immunotherapy for the treatment of advanced breast cancer.